drugset
drugset / Trial / NCT05156034

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

NCT05156034 ↗

Phase 1 Terminated 16 enrolled Sarkana Pharma Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of SRK-001 in Healthy Participants.

Timeline

Start
2021-12-21
Primary completion
2022-09-05
Completion
2022-09-05

Outcome

Outcome not reported

Stopped: “Due to occurrence of eye related adverse events.”

Drugs

EvaluationDrugModalityDoseRoute
Subject SRK-001 Unknown — Intravenous

Indications

No indication recorded.